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evidence that modulation of the immune 
response is beneﬁcial, suggests that future 
therapies can be based on this modula-
tion (Figure 1). As continuing research 
unravels the plethora of mechanisms at 
play, the number of targets and potential 
treatment opportunities will increase. 
Strategies that target each step of the 
recruitment, activation, and modula-
tion of the inﬂammatory response are 
possible. Among the opportunities for 
salutary intervention in renal I/R injury 
as highlighted by the study of Sandovici 
et al.1 is a strategy that alters the balance 
between pro- and anti-inflammatory 
aspects of the response to such injury. A 
cautionary note must be sounded, as such 
modulation of the immune system may 
have unintended and long-term conse-
quences. IL-13 alterations may interfere 
with the normal clearance of pathogens, 
since IL-13 potently inhibits the normal 
T-helper type 1 response to invading 
pathogens. Nevertheless, as I/R injury 
is the leading cause of acute renal failure 
and determinant of the outcome after 
renal transplantation, every opportunity 
should be investigated in the pursuit of 
novel treatments.
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The purpose of this Commentary is to briefly summarize the current 
knowledge of nephrogenic systemic fibrosis in order to promote better 
understanding of the complexity of chronic kidney disease and its 
associated conditions.
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Although recognized as a clinical entity in 
1997, nephrogenic systemic ﬁbrosis (NSF) 
was not reported in the literature until 
2000.1 First termed nephrogenic ﬁbros-
ing dermopathy, the condition was char-
acterized by extensive cutaneous ﬁbrosis 
mimicking scleroderma but with notable 
sparing of the face and neck, absence of 
scleroderma-associated autoantibodies, 
and absence of local inﬂammation (his-
tologically). Over the past 7 years it has 
become clear that nephrogenic ﬁbrosing 
dermopathy does not exclusively aﬀect 
the skin. Evidence of sclerosis has been 
identiﬁed in lungs, heart, liver, and mus-
cles, and therefore the term NSF better 
describes the systemic nature of the con-
dition.2 Because of the devastating nature 
of the disease, in less than one decade it 
has gone from a state of obscurity to one 
of common parlance among nephrolo-
gists, dermatologists, and radiologists. 
Notwithstanding, the pathobiology of 
NSF remains incompletely understood.
Current state
The link to gadolinium-containing con-
trast agents (GCCAs), ﬁrst established in 
2006,3 has led several regulatory bodies to 
issue practice-altering recommendations. 
In its communiqué dated 23 May 2007, 
the United States Food and Drug Admin-
istration advises health-care professionals 
to avoid using GCCAs in persons at risk 
for the development of NSF, to evaluate 
patients for renal dysfunction, to not 
exceed the recommended GCCA dose in 
product labeling, and to consider prompt 
hemodialysis after administration of a 
GCCA.4 The American College of Radi-
ology has issued a similar recommenda-
tion. In this era of increasing attention 
to patient safety and rapid disclosure of 
medical error, these recommendations 
have necessarily emphasized the need for 
a highly conservative approach to the use 
of gadolinium.
It is important to maintain an appro-
priate perspective, understand this con-
dition, and deal with it in a systematic 
evidence-based manner. In particular we 
need to ask a series of questions to move 
the inquiry from phenomenology to epi-
demiology to pathobiology expeditiously 
so that we can understand and prevent 
the occurrence of NSF. With ongoing 
publication of progressively sophisti-
cated analyses of cases, case series, and 
databases, we should be able to accom-
plish this in the near future (Figure 1). 
In a manner akin to that of the recent 
recognition, and subsequent diminution, 
of the incidence and severity of erythro-
poietin-associated pure red-cell aplasia, 
the nephrology community again has a 
unique opportunity to understand and 
prevent a rare condition. We must hypoth-
esize what key factors create the ‘perfect 
storm’ from which the disease phenotype 
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emerges. Thus, we must ask and answer 
a series of questions: why now, why this 
patient group, and what we can do diﬀer-
ently to avoid further harm. Importantly, 
perhaps this condition will help to draw 
attention to the uniqueness of the chronic 
kidney disease population with respect to 
handling of any substance, and caution all 
as to the need for thorough investigations 
prior to widespread use.
The true denominator
We know that in 2006, 26.9 million mag-
netic resonance imaging scans were per-
formed in the United States, and over 200 
million were performed worldwide.5 Since 
2000, more than 215 discrete cases of NSF 
have been described in the literature.6 
Thus, using the true denominator, this 
condition is extraordinarily rare. Nonethe-
less, the incidence in those with markedly 
reduced kidney function is substantially 
higher, which has alerted us to the unique 
pathophysiology of this condition.
Patients with the condition are on dial-
ysis, have hepatorenal syndrome, or have 
acute kidney injury and require dialysis. 
Interestingly, it appears that the presence 
of mild acidosis may be an important fac-
tor in some cases.3 Ongoing case reports 
have also associated NSF with exposure to 
erthropoiesis stimulating agents (ESAs), 
angiotensin-converting enzyme inhibi-
tors, and recent vascular procedures.7 
However, considering the widespread 
use of ESAs and angiotensin-converting 
enzyme inhibitors and the large number 
of vascular procedures undertaken, the 
number of cases of NSF is, again, vanish-
ingly small. Furthermore, the majority 
of cases have been linked to two agents: 
gadodiamide and gadopentate.5 They 
have specific characteristics that dif-
ferentiate them from other gadolinium 
compounds (see below).
Gadolinium has now been identi-
ﬁed in the skin samples of patients with 
NSF.8,9 Given the large number of dialysis 
patients, a high population prevalence of 
estimated glomerular ﬁltration rate less 
than 30 ml/min, and the liberal use of 
gadolinium, what are the unique features 
that lead to the occurrence of NSF in such 
a limited number of individuals? This 
remains the question to be answered in 
future studies.
Pathobiology and chemistry
Gadolinium (atomic number 64, aver-
age atomic weight 157.25 g/mol) is a 
member of the lanthanide series. Ionized 
gadolinium, which exists in an oxidation 
state of 3+, is highly toxic, impairing cal-
cium channel function with documented 
cardiovascular and neurological toxic-
ity.5 This toxicity has been attributed to 
the comparable ionic radii of Ca2+ and 
Gd3+,10 which are, respectively, 112 pm 
and 105 pm (for a coordination number 
of 8).11 Therefore, for safe use in humans, 
Gd3+ is chelated, which confers water sol-
ubility and decreases the toxicity about 
30-fold in animal studies.12 Interestingly, 
not all gadolinium chelates are created 
equal. There are two structural classes, 
referred to as ‘linear’ and ‘macrocyclic.’ 
Both types of chelates form nine-coordi-
nate complexes with the solvent (water) 
as one of the ligands, but the macrocyclic 
compounds coordinate Gd3+ in a pre-
formed cavity.13
Linear chelates have been observed 
to have lower thermodynamic stability, 
as recently reviewed.14 Of the ﬁve Food 
and Drug Administration-approved 
chelates, the linear chelate gadodiamide-
diethylene triamine pentaacetic acid 
(DTPA) (Omniscan) is the most fre-
quently associated with NSF.5 It also has 
the largest dissociation constant and, 
accordingly, the shortest half-life of its 
coordination complex.14 Interestingly, 
gadodiamide-DTPA is formulated with 
12 mg/ml of excess ligand, presumably 
to decrease the probability of free Gd3+ 
forming.7 Gadopentate-DTPA, the com-
plex implicated in NSF with the second 
greatest frequency,5 shares the features 
of linear structure and lower thermo-
dynamic stability with gadodiamide-
DTPA.14 Therefore, the structure of the 
coordinating ligand and the associated 
lowering in the thermodynamic stabil-
ity of the coordination complex appear 
to make linear chelates more susceptible 
to the transmetalation process,14 which 
underpins the pathogenesis of NSF.
However, it should be emphasized that 
patient factors certainly also play a role 
in Gd3+ exposure. In people with normal 
renal function, gadolinium chelates have 
a half-life of 1.3 hours. However, with 
reducing glomerular ﬁltration rate, this 
clearance time is increased, and in dialy-
sis patients, GCCA half-life is extended 
to between 30 and 120 hours.7 Thus, in 
those with chronic kidney disease, the 
slow clearance of GCCA provides a pro-
tracted time period in which transmetal-
ation may occur. This may be why NSF 
aﬀects those with low glomerular ﬁltra-
tion rates with such predominance.
Naturally, the transmetalation process 
is facilitated by those ions that substitute 
for Gd3+ in the metal complex. In vivo, 
the proposed ions have been those of cal-
cium, zinc, iron, copper, and aluminum.7 
Figure 1 | Iterative process for understanding rare phenomena.
Pathobiology
Epidemiology
Denominator at risk
Systematic collection
of descriptive data  
• Isolated case
• Case series
• Clinical review
• Phenotype and
  hypothesis generation
• Tissue investigation
Phenomenon
described
Inorganic chemistry
Testing of hypotheses in
animal models 
Kidney International (2008) 73          1337
commentar y
Transmetalation occurs more quickly in 
acidic conditions.14 Thus it is conceivable 
that in the clinical context of chronic kid-
ney disease, where patients are frequently 
acidotic and regularly receive boluses 
of intravenous iron products, the trans-
metalation process might be facilitated.
The study by Swaminathan et al.15 (this 
issue) extends observations previously 
made regarding gadolinium tissue depo-
sition and the association of gadolinium-
induced iron mobilization and transferrin 
oversaturation.16 The authors hypoth-
esized that the mobilization of free iron 
may have furthered the process of trans-
metalation, leading to deposition of free 
gadolinium and iron in tissues aﬀected 
by NSF.16 The subsequent inﬂammation, 
oxidative stress, and tissue injury induced 
by this deposition may lead to perpetua-
tion of the NSF process. Furthermore, the 
authors are able to demonstrate staining 
of metals in tissue samples to corroborate 
this hypothesis.
The retrospective analysis of 32 cases 
of NSF identified at their institution 
describes a high mortality, due to either 
cardiovascular causes or sepsis.15 Autopsy 
results of three patients are presented and 
are compared with those of normal con-
trols. Gadolinium and iron were isolated 
in skin and in the heart, aorta, and other 
organs. Furthermore, coronary artery 
staining revealed the presence of CD34+ 
ﬁbroblasts, the same cells that are upregu-
lated in sclerotic areas. The controls did 
not have any of these ﬁndings, but note 
that they were not on dialysis and did not 
have exposure to GCCA. If multisystem 
deposition of gadolinium elicits a local 
inﬂammatory response leading to ﬁbrosis 
not only of skin but of organs and vascu-
lature, it may be that GCCA accelerates 
cardiovascular mortality in an already 
susceptible population. The specific 
compounds used, in combination with 
an internal milieu (acidosis, presence of 
iron in excess quantities, and so on), may 
have created a unique pathobiological 
state that leads to NSF.
Epidemiology and future research 
methods
Since the advisory warnings, and the 
reduction or cessation of use of gado-
diamide in susceptible populations, the 
incidence appears to be reduced. Is this 
because fewer people are undergoing 
magnetic resonance imaging testing if they 
are in a high-risk category, or is it because 
those that do have been more carefully 
evaluated, the compound changed, and/
or dialysis instituted quickly?
The creation and maintenance of inter-
national registries, with the capacity to 
collect key clinical information as well 
as biological samples in patients both 
affected and unaffected but with simi-
lar exposures, is imperative if we are to 
understand this rare condition in a time 
of quickly changing practices. The current 
NSF Registry in Boston is an example of 
this kind of initiative (http://www.icnfdr.
org), though more comprehensive inves-
tigation of all exposed, not simply those 
with the condition, could be undertaken.
Ideally, one needs to study hemodialy-
sis patients with exposure to GCCAs but 
without the clinical condition to deter-
mine what is epiphenomenon, what is 
pathological, and what phenotype (and 
eventually what genotype) is at highest 
risk from GCCA exposure.
Summary
Nephrology patients have a multiplicity 
of conditions that contribute to morbidity 
and mortality. In addition, they require 
ongoing evaluation and interventions and 
treatments for speciﬁc conditions. They 
are unique in that their internal milieu 
is drastically altered, they are exposed to 
multiple medications, oxidative stresses, 
and non-natural materials (catheters, 
dialyzers), and their ability to excrete 
ingested or infused substances is limited. 
Even those therapies that we believe to be 
innocuous, or helpful need to be studied 
carefully in speciﬁc situations known to 
aﬀect chronic kidney disease patients. 
The story of gadolinium-induced NSF is 
another example of a rare but devastating 
phenomenon occurring in small num-
bers of patients, but at an extraordinary 
rate in a speciﬁc population. This is yet 
another opportunity to better understand 
the interaction of internal and external 
environment, complex chemical reac-
tions, and the inﬂuence of genotype on 
disease expression.
The gadolinium story as it relates 
to NSF will continue to unfold. More 
extensive understanding of the processes 
and related pathobiology will emerge. As 
an international nephrology community, 
we need to facilitate the collection of data 
and the development of clinical and bio-
logical registries, and to support better 
understanding of rare conditions.
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